Antibodies to cd70
AssigneeArgen-X N.V.
InventorsKaren SILENCE, Peter ULRICHTS, Johannes Joseph Wilhelmus DE HAARD, Torsten DREIER, Michael John Scott SAUNDERS, Harald WAJANT, Sofie Maria Elvire GABRIELS, Mahan MOSHIR
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
Claims22
An isolated polynucleotide that encodes an antibody, or an antigen binding fragment thereof which binds to human CD70, said antibody or antigen binding fragment comprising at least one heavy chain variable domain (VH) and at least one light chain variable domain (VL), wherein said VH and VL domain, when tested as a Fab fragment, exhibit an off-rate (koff measured by Biacore) for human CD70 of less than 7×10−4 s−1.
(canceled)
5-7. (canceled)
An isolated polynucleotide that encodes an antibody or antigen binding fragment thereof, which binds to CD70, said antibody or antigen binding fragment comprising a heavy chain variable domain comprising a variable heavy chain CDR3, a variable heavy chain CDR2 and a variable heavy chain CDR1, wherein said variable heavy chain CDR3 comprises an amino acid sequence selected from the group consisting of:
- SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:262 and SEQ ID NO:263, and sequence variants of any one of the recited sequences, wherein the sequence variant comprises one, two or three amino acid substitutions in the recited sequence;
- said variable heavy chain CDR2 optionally comprises an amino acid sequence selected from the group consisting of:
- amino acid sequences of SEQ ID NO:
- 306 [X1X2X3X4X5X6X7X8X9 YYADSVKX10], wherein
- X1 is any amino acid, preferably D, T, S or E,
- X2 is any amino acid, preferably I,
- X3 is any amino acid, preferably N, S, T or Y,
- X4 is any amino acid, preferably N, M, S or T,
- X5 is any amino acid, preferably E, D, Y or H,
- X6 is any amino acid, preferably G, D, S or N,
- X7 is any amino acid, preferably G, Y, S, D or M,
- X8 is any amino acid, preferably T, E, S, N, Y or R,
- X9 is any amino acid, preferably T, A or R, and
- X10 is any amino acid, preferably G or S,
- and the amino acid sequences of SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:249, SEQ ID NO:258 and SEQ ID NO:259 and sequence variants of any one of the recited sequences, wherein the sequence variant complises one, two or three amino acid substitutions in the recited sequence;
- and
- said variable heavy chain CDR1 optionally comprises an amino acid sequence selected from the group consisting of:
- amino acid sequences of SEQ ID NO:
- 307 [X1YYMN], wherein
- X1 is any amino acid, preferably V, G or A,
- amino acid sequences of SEQ ID NO:
- 308 [X1X2AMS], wherein
- X1 is any amino acid, preferably D, T, S, N or G and
- X2 is any amino acid, preferably Y, S or P,
- and the amino acid sequences of SEQ ID NO:10, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:248, SEQ ID NO:256 and SEQ ID NO:257 and sequence variants of any one of the recited sequences, wherein the sequence variant comprises one, two or three amino acid substitutions in the recited sequence.
22-23. (canceled)
25-49. (canceled)
Dependencies are inferred from the claim text.